CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Capricor upgraded at Oppenheimer as Deramiocel review extended

RegulatoryDeramiocelPositive
AI Analysis

Summary

Oppenheimer upgraded Capricor as the FDA extended its review of Deramiocel. The extension suggests ongoing regulatory evaluation without immediate approval.

Outcome Details

Review extended

Importance:6/10
Sentiment:
0.30
FDA reviewextensionupgraderegulatory
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 25, 2026 12:26 PM

Read Original